Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Clinical trial NCT05663775 · RECRUITING

Trial details

NCT number: NCT05663775
Sponsor: AHS Cancer Control Alberta
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Immune-related Adverse Event Diarrhea Advanced Melanoma Advanced Rectal Carcinoma

Start date: 2024-08-20
Primary completion: 2026-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.